(Reuters) - Levels of a protein believed to be a main cause of Alzheimer's disease rose in the blood of patients treated with Eli Lilly's experimental drug in late-stage trials, suggesting the protein ...
Top drugmakers have spent more than a decade investigating and advancing anti-amyloid Alzheimer's medicines in clinical ...
While many pharma and biotech companies developing drugs to treat Alzheimer's disease are targeting amyloid beta plaque, Eli Lilly (NYSE:LLY) is looking at other targets as well. The drugmaker's ...
The opinion will now be referred to the European Commission for final regulatory decision on donanemab INDIANAPOLIS, July 25, 2025 /PRNewswire/ -- Eli Lilly and Company (LLY) announced today that the ...
Drugs once hailed as a breakthrough in the fight against Alzheimer's disease do not meaningfully help patients, a major ...
U.S. pharmaceutical company Eli Lilly is expected to unveil the top-line results (key findings from phase 3 clinical trials) of its new drug component ‘Lemternectuk’, being developed as a successor to ...
A collage of dartboards in different colors and sizes with a few partly broken darts and a pile of darts lying underneath them. The frame of the illustration is a profile of someone’s head, with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results